PE-22-28 10mg
Spadin-Derived TREK-1 Blocker for Antidepressant Research
PE-22-28 is a synthetic analogue of Spadin that blocks TREK-1 (KCNK2) potassium channels in the brain, producing rapid antidepressant effects in animal models comparable to SSRIs but with a faster onset and unique mechanism.
Spadin-Derived TREK-1 Blocker for Antidepressant Research
TREK-1 is a two-pore domain potassium channel whose blockade increases serotonergic neurotransmission. PE-22-28 was engineered to enhance CNS penetration and TREK-1 binding affinity versus natural Spadin, producing robust antidepressant, anxiolytic, and memory-enhancing effects in rodents.
As one of the most studied compounds in the longevity research space, PE-22-28 has attracted sustained scientific interest across Antidepressant mechanism research, TREK-1 channel studies, Serotonergic system research. Peer-reviewed evidence indicates that antidepressant effects in forced swim test models, which has positioned PE-22-28 as a reference standard for researchers exploring antidepressant mechanism research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
PE-22-28 Documented Benefits: 3 Documented Mechanisms
TREK-1 Channel Blockade
Inhibits TREK-1 potassium channels, increasing serotonergic firing and antidepressant signaling.
Rapid Antidepressant Effect
Faster onset than SSRIs in animal models, with effects seen after single doses.
Memory Enhancement
Improves spatial memory and learning in rodent behavioral tests.
How PE-22-28 Works: Molecular Mechanism & Pathway
TREK-1 two-pore potassium channel antagonist derived from Spadin; inhibits TREK-1 in the raphe nuclei to increase serotonergic neurotransmission and antidepressant signaling.
The 3 primary research pathways identified for PE-22-28 — TREK-1 Channel Blockade, Rapid Antidepressant Effect, Memory Enhancement — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that faster onset than fluoxetine in rodent models, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, PE-22-28's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
PE-22-28 is routinely studied alongside DSIP and NA-Selank in longevity-focused compound panels. Researchers investigating antidepressant mechanism research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that also shows anxiolytic and nootropic properties has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All PE-22-28 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Antidepressant effects in forced swim test models
- Faster onset than fluoxetine in rodent models
- Also shows anxiolytic and nootropic properties
Ideal For
- Antidepressant mechanism research
- TREK-1 channel studies
- Serotonergic system research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on PE-22-28. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Antidepressant effects in forced swim test models
Faster onset than fluoxetine in rodent models
Also shows anxiolytic and nootropic properties
Third-Party Verified Every Batch
Each vial of PE-22-28 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
